Overview / Abstract: |
With numerous recent advances in available treatments and options for diagnosis and staging, disease monitoring, and supportive care, the outlook for patients with multiple myeloma has never been brighter. However, this expansion of clinical options has also introduced potentially daunting challenges for the health care providers charged with the care of these patients. This activity presents a robust roundtable discussion in which our expert faculty provides insights on such issues as determining the optimal timing and approach for autologous stem cell transplantation (ASCT), considering new factors when weighing the benefits and risks of maintenance therapy, and choosing between the various therapeutic options in the relapsed/refractory setting. This activity includes downloadable resources (including supplemental figures and tables). |
Expiration |
Dec 27, 2018 |
Discipline(s) |
Nurse Practitioner , Physician CME, Physician Assistant CME |
Format |
Online |
Credits / Hours |
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine, RedMedEd, and the Multiple Myeloma Research Foundation. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.Penn State College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. |
Accreditation |
ACCME |
Presenters / Authors / Faculty |
Amrita Y. Krishnan, MD Gareth J. Morgan, MD, PhD Saad Z. Usmani, MD, FACP |
Activity Specialities / Related Topics |
Education / Teaching, Hematology, Oncology / Cancer / Radiation Therapy |
Sponsors / Supporters / Grant Providers |
Support for this activity has been provided through educational grants from Amgen, Celgene Corporation, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. |
Keywords / Search Terms |
RedMedEd RedMedEd, MMRF, MM, multiple myeloma, stem cell transplantation, maintenance therapy, relapsed/refractory disease, relapsed/refractory MM, oncology, hematology, Free, CME, CE, multiple myeloma patients, ASCT, autologous stem cell transplantation, novel agent, monoclonal antibody Free CE CME |